Loading...
•
Sep 30, 2021
Viking Therapeutics Q3 2021 Earnings Report
Announced financial results for the third quarter and nine months ended September 30, 2021, and provided a corporate update.
Key Takeaways
Viking Therapeutics reported a net loss of $13.2 million, or $0.17 per share, for the three months ended September 30, 2021. The company ended the quarter with approximately $216 million in cash, cash equivalents and short-term investments.
Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH is proceeding.
Phase 1b Proof-of-Concept Trial Evaluating VK0214 in X-ALD Patients is underway.
Data from new program evaluating novel dual agonists for metabolic disorders was presented at ObesityWeek® 2021.
The company's balance sheet remains strong, supporting the advancement of clinical programs into late-stage development.
Viking Therapeutics
Viking Therapeutics
Forward Guidance
Viking plans to initiate clinical development of a lead candidate from the dual incretin receptor agonists program in the coming months.